Shares of Sun Pharma Advanced Research Company (SPARC) rise as much as 4.8 percent to Rs 404.9, biggest daily percent gain in nearly a week.
Pharma research & development co expects to file with US Food and Drug Administration its new drug application for cancer drug Taclantis by Q4 2019, it said here in a presentation on Tuesday.
Co says deadlines for U.S. FDA to review ocular hypertension drug Xelpros and anti-epileptic agent Elepsia as November 2018 and January 2019, respectively.
SPARC seems to be nearing monetization of its lead products, Morgan Stanley says in note.
Sun Pharmaceutical Industries should benefit from the potential FY 2019 commercialization of two mid-sized lead assets (Xelpros and Elepsia XR), Morgan Stanley adds.
SPARC was demerged from Sun Pharma in 2006, both firms share same parent.
Sun Pharma shares rise as much as 2.5 percent to Rs 671.8.
Also, catch all the action and updates in our Market Live blog.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Odisha's new CM — who is Mohan Charan Majhi and what prompted the BJP to choose him
Jun 13, 2024 2:54 PM
Election 2024: 504 out of 543 newly-elected MPs are ‘crorepatis’ – Check 10 richest members in 18th Lok Sabha
Jun 12, 2024 9:55 PM
BJP to start nationwide organisational rejig, new party president to be elected soon
Jun 12, 2024 9:31 AM
New Lok Sabha Speaker to be elected in special 8-day session: Report
Jun 11, 2024 6:28 PM